Alphamab Oncology

9966 · HKEX

Public Market Listing

9966HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Alphamab Oncology are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
HER2 (biparatopic — extracellular domains II and IV)Antibody–drug conjugate
Breast CancerColorectal Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Phase 3
PD-L1 + CTLA-4Multispecific antibody
Non-Small Cell Lung Cancer
Phase 2
HER3 + TROP2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
HER2 (JSKN003 ADC component) + PD-L1 (envafolimab component)Combination
Non-Small Cell Lung Cancer

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Anbenitamab repodatecanPhase 3Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers
Est. primary completion 2026-12-30 · NCT06751485 · CT.gov ↗
What to watch
JSKN033Phase 1/2Advanced Malignant Tumors
Est. primary completion 2026-12-31 · NCT06770881 · CT.gov ↗
What to watch
2027 (5)
June 2027 (2)
JSKN016Phase 1/2Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
Est. primary completion 2027-06-30 · NCT06942234 · CT.gov ↗
What to watch
JSKN016Phase 2Advanced Non-small Cell Lung Cancer
Est. primary completion 2027-06-30 · NCT06775483 · CT.gov ↗
What to watch
August 2027 (1)
JSKN033Phase 2Non Small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-08-30 · NCT07283198 · CT.gov ↗
What to watch
October 2027 (1)
JSKN033Phase 2Cervical Cancer
Est. primary completion 2027-10 · NCT07497074 · CT.gov ↗
What to watch
December 2027 (1)
JSKN016Phase 1/2Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Est. primary completion 2027-12 · NCT07336771 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
JSKN033Phase 3Recurrent or Metastatic Cervical Cancer
Est. primary completion 2028-12 · NCT07797153 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
JSKN016Phase 3Triple Negative Breast Cancer
Est. primary completion 2029-03-17 · NCT07533123 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 May 2024Topline resultKN046Phase 3 KN046-303 overall survival result
Alphamab Oncology · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$44M$35M$230M—report ↗

Alphamab Oncology reported total revenue of RMB 319.44 million for the six months ended June 30, 2025, up 84.05% YoY, with product revenue attributable to the Company of RMB 67.02 million. R&D expenditure reached RMB 253.16 million, up 30.14% YoY, and the company recorded a profit of RMB 21.58 million versus a loss of RMB 44.90 million in H1 2024, representing a year-on-year turnaround from loss to profit. Cash reserves stood at RMB 1,644.79 million as of June 30, 2025.

Business progress included KN026’s phase II/III trial meeting its primary endpoint in HER2-positive gastric cancer, with an NDA submission planned for that indication, and JSKN003 advancing multiple phase III trials in breast and ovarian cancer while receiving U.S. FDA orphan drug designation for gastric cancer. Envafolimab data were presented at ASCO, JSKN016 completed enrollment in HER2-negative breast cancer cohorts, and JSKN033 progressed through dose escalation. The company also outlined 2025 milestones including pivotal study filings for JSKN016 and JSKN003, and initiation of a phase I study for JSKN022.

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$193M$16Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$89M$56M$215M—report ↗